deepull secures oversubscribed €50 million Series C financing to advance UllCORE diagnostic system for direct-from-blood rapid pathogen detection Round co-led by Columbus Venture Partners, Panakès ...

The financing will enable Nova Anchora to advance its lead candidate NvA-011, a recombinant collagen therapy, through IND-enabling studies. The investment underscores the backers’ commitment to ...

In addition, a further 1,220,000 options have been granted under a non-tax advantaged option scheme. These options also have a vesting period of 2 years with one third vesting on grant, one third on ...

The Board of Directors of Financière de Tubize appoints Bruno Holthof as new Chair ...

Basel, 29 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for the VENTANA® TROP2 (EPR20043) ...

Le Conseil d'Administration de la Financière de Tubize nomme Bruno Holthof comme Président ...

Allschwil, Switzerland – April 29, 2025 Idorsia Ltd (SIX: IDIA) today announced the publication of “ Effect of daridorexant on nighttime wakefulness and next-morning sleepiness: assessing the ...

Blurriness & Eye Focus: Today’s screen-heavy lifestyle can often stress the eyes, sometimes leading to mild blurriness and difficulty focusing. Lumineye’s sublingual nano-formulation is designed to ...

FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...

Statistical evidence from meta-analysis of VIVIAD and VIVA-MIND enables efficient design of Phase 2b study in diabetic kidney disease (DKD), ideally suited to evaluate varoglutamstat in the intended ...

Pratteln, Switzerland, April 29, 2025 – Santhera Pharmaceuticals (SIX: SANN) today published the invitation to its Annual General Meeting (AGM), which will be held on May 20, 2025, at 10:00 CEST at ...

The data presented at the AACR Annual Meeting show that amezalpat reduced tumor promoting immunosuppression by M2 macrophages and T regulatory cells resulting in immune activation. These data support ...